Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 2/20 | 0.46 |
| ▸ | ECE1 | P42892 | 2/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3800888 | 1.00 | MMP12 (0.46) | MMP12ECE1MKNK1MKNK2LMNA | |
| SCHEMBL2440911 | 1.00 | MMP12 (0.46) | MMP12ECE1MKNK1MKNK2LMNA | |
| SCHEMBL3800894 | 1.00 | MMP12 (0.46) | MMP12ECE1MKNK1MKNK2LMNA | |
| SCHEMBL3804480 | 0.89 | ROCK1 (0.47) | MKNK2CCR1 | |
| SCHEMBL3800008 | 0.89 | ROCK1 (0.47) | MKNK2CCR1 | |
| SCHEMBL3800006 | 0.89 | ROCK1 (0.47) | MKNK2CCR1 | |
| SCHEMBL3804477 | 0.89 | ROCK1 (0.47) | MKNK2CCR1 | |
| SCHEMBL3804366 | 0.89 | CYP3A4 (0.55) | MMP12ECE1CYP3A4 | |
| SCHEMBL3804358 | 0.89 | CYP3A4 (0.55) | MMP12ECE1CYP3A4 | |
| SCHEMBL3795178 | 0.87 | CCR1 (0.42) | CYP3A4CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| EP-1697344-B1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2266971-A2 | Hiv protease inhibiting compounds | Abbott Laboratories (US) | 2010-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | SERPINB1, HPN, DNPEP | MMP12 130/4885ECE1 343/4885MKNK1 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.